SCYNEXIS

SCYNEXIS Liabilities

The The Liabilities of SCYNEXIS (SCYX) as of Sep 27, 2026 is 9.65 M USD. In the previous year, The Liabilities was 35.57 M USD — a change of -72.86% (lower).

Liabilities

9.65 MUSD

YoY

-72.86%

Last updated:

In 2026, SCYNEXIS's total liabilities amounted to 9.65 M USD, a -72.86% difference from the 35.57 M USD total liabilities in the previous year.

The SCYNEXIS Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
21.95 M USD
Jan 1, 2019
44.26 M USD
Jan 1, 2020
79.78 M USD
Jan 1, 2021
78.58 M USD
Jan 1, 2022
84.58 M USD
Jan 1, 2023
55.45 M USD
Jan 1, 2024
35.57 M USD
Jan 1, 2025
9.65 M USD
The SCYNEXIS Liabilities history
YEARLiabilitiesYoY
9.65 MUSD-72.86%
35.57 MUSD-35.86%
55.45 MUSD-34.44%
84.58 MUSD+7.63%
78.58 MUSD-1.50%
79.78 MUSD+80.26%
44.26 MUSD+101.68%
21.95 MUSD-10.21%
24.44 MUSD-2.13%
24.97 MUSD+240.97%
7.32 MUSD+17.35%
6.24 MUSD—
Access this data via the Eulerpool API

SCYNEXIS Stock analysis

What does SCYNEXIS do? SCYNEXIS Inc is a biopharmaceutical company that focuses on the discovery and development of novel therapeutics for serious infectious diseases and cancer. The company was founded in 2000 and is headquartered in New Jersey, USA. SCYNEXIS is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing SCYNEXIS's Liabilities

SCYNEXIS's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating SCYNEXIS's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing SCYNEXIS's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

SCYNEXIS's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in SCYNEXIS’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about SCYNEXIS stock

The Liabilities of SCYNEXIS is 9.65 M USD in 2026.

The Liabilities of SCYNEXIS changed from 35.57 M USD to 9.65 M USD, representing a -72.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities SCYNEXIS since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's SCYNEXIS historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — SCYNEXIS

All Key Metrics — SCYNEXIS